Anterior Segment Complications Following Intravitreal Injection

被引:0
|
作者
Mackenbrock, Lars H. B. [1 ]
Auffarth, Gerd U. [1 ]
Albrecht, Michael [1 ]
Naujokaitis, Tadas [1 ]
Kessler, Lucy J. [1 ]
Mayer, Christian S. [1 ]
Khoramnia, Ramin [1 ]
机构
[1] Univ Hosp Heidelberg, Dept Ophthalmol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany
关键词
intravitreal injection; anti-VEGF; cataract; complication; intraocular inflammation; vitreous; POSTERIOR CAPSULE RUPTURE; INTRAOCULAR INFLAMMATION; TRIAMCINOLONE ACETONIDE; BILATERAL VASCULITIS; CHAMBER MIGRATION; RISK-FACTORS; BEVACIZUMAB; RANIBIZUMAB; MANAGEMENT; SYSTEMS;
D O I
10.1055/a-2349-2224
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Intravitreal injections (IVI s) have gained increased popularity in the past decades and are used to treat a multitude of ailments. In 2010, the total number of IVI s surpassed the number of cataract surgeries performed, making it the most common procedure in ophthalmology. As the number of injections increases, so does the number of injected-related complications. While complications in the posterior segment, such as retinal detachment or endophthalmitis, are detrimental to visual function and have therefore been well documented, IVI s can also lead to complications in the anterior segment. These include hyphema, inflammation of the sterile anterior segment (incidence rate of 0.05 to 1.1% depending on the drug), implant migration with corneal decompensation (incidence rate of 0.43%), iatrogenic lens damage (incidence rate of 0.07%), accelerated cataract formation (up to 50% for steroids and 10.9% for anti-VEGF), and an increased complication rate during subsequent cataract surgery (up to 4% per IVI). Most of these complications occur immediately and have a good prognosis if treated correctly. However, the increased risk of complications during subsequent surgery demonstrates that IVI s can also have long-term complications, a topic that needs to be explored further in future research projects.
引用
收藏
页码:917 / 922
页数:6
相关论文
共 50 条
  • [41] Ptosis following an intravitreal injection of triamcinolone acetonide
    F Viola
    F Morescalchi
    R Ratiglia
    G Staurenghi
    Eye, 2007, 21 : 421 - 423
  • [42] Endophthalmitis Following Intravitreal Injection: An Unusual Organism
    Martyn, L.
    Alarrayedh, H.
    Townley, D.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2018, 187 : S8 - S9
  • [43] Ptosis following an intravitreal injection of triamcinolone acetonide
    Viola, F.
    Morescalchi, F.
    Ratiglia, R.
    Staurenghi, G.
    EYE, 2007, 21 (03) : 421 - 423
  • [44] Bilateral vasculitis following intravitreal brolucizumab injection
    Kessler, L. J.
    Mayer, C. S.
    Son, H. S.
    Auffarth, G. U.
    Khoramnia, R.
    OPHTHALMOLOGE, 2022, 119 (SUPPL 1): : 93 - 97
  • [46] Intraocular inflammation following intravitreal injection of bevacizumab
    Sophie J. Bakri
    Theresa A. Larson
    Albert O. Edwards
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2008, 246 : 779 - 781
  • [47] Oculometric alterations following intravitreal triamcinolone injection
    Cekic, Osman
    Bardak, Yavuz
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2010, 94 (10) : 1408 - 1409
  • [48] Silicone oil droplets following intravitreal injection
    Freund, K. Bailey
    Laud, Ketan
    Eandi, Chiara M.
    Spaide, Richard F.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2006, 26 (06): : 701 - 703
  • [49] Pseudohypopyon following intravitreal triamcinolone acetonide injection
    Sharma, MC
    Lai, WW
    Shapiro, MJ
    CORNEA, 2004, 23 (04) : 398 - 399
  • [50] OCULAR FINDINGS FOLLOWING INTRAVITREAL SILICONE INJECTION
    LAROCHE, L
    PAVLAKIS, C
    SARAUX, H
    ORCEL, L
    ARCHIVES OF OPHTHALMOLOGY, 1983, 101 (09) : 1422 - 1425